The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity
工程化的 CD80 变体融合治疗药物达沃西普 (davoceticept) 将检查点拮抗作用与条件性 CD28 共刺激相结合,以产生抗肿瘤免疫力
期刊:Nature Communications
影响因子:14.7
doi:10.1038/s41467-022-29286-5
Mark F Maurer, Katherine E Lewis, Joseph L Kuijper, Dan Ardourel, Chelsea J Gudgeon, Siddarth Chandrasekaran, Sherri L Mudri, Kayla N Kleist, Chris Navas, Martin F Wolfson, Mark W Rixon, Ryan Swanson, Stacey R Dillon, Steven D Levin, Yengo Raymond Kimbung, Masato Akutsu, Derek T Logan, Björn Walse,